Randomised trial of two induction therapy regimens for high-risk neuroblastoma HR-NBL1.5 …

Written By Carla Aguilera

International Society of Paediatric Oncology European Neuroblastoma Group Study

Alberto Garaventa, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Martin Elliott, Shifra Ash, Godfrey CF Chan, Geneviève Laureys, Maja Beck-Popovic, Kim Vettenranta, Walentyna Balwierz, Henrik Schröder, Cormac Owens, Cesen Maja, Vassilios Papadakis, Toby Trahair, Gudrun Schleiermacher, Peter Ambros, Stefania Sorrentino, Andrew DJ Pearson, Ruth Ladenstein,

 J Clin Oncol . 2021 Aug 10;39(23):2552-2563. doi: 10.1200/JCO.20.03144. Epub 2021 Jun 21.

Carla Aguilera
Previous

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the SIOPEN HR-NBL-1 trial
Next

Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience